News

Isunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.

Clinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.

We really are at a crossroads in eye healthcare. Wouldn’t a virtual exam be ‘just as good’ as a trip to the eye doctor? To today’s busy consumer, how can we justify leisurely sitting in front of a computer or in a kiosk versus an in-office visit that takes sixty plus minutes and includes that awkward part – dilation?

Looking for summer reading suggestions? Find out what books your colleagues are reading!

Clinicians continue to explore the relationship between IOP and cerebrospinal fluid pressure in glaucoma.

In a study including 23 eyes with a transscleral micro-lumen aqueous drainage tube after failing maximum tolerated medication, reductions in the mean IOP were observed as well as in the mean number of medications per day.

My position is that murdering people with poison is a terrible thing, even if the victim is an annoying parent, mother-in-law, or department chair. It's morally wrong, plus the penalty would likely be severe (suspension of operating privileges or even being fired-unless, of course, you have tenure). Yet ophthalmologists certainly have the means to go around poisoning folks.

Ab-interno canaloplasty (ABiC) is a minimally invasive glaucoma surgery that accesses, catheterizes, and viscodilates all sites controlling aqueous outflow. When performed alone for uncontrolled glaucoma or with cataract surgery, it can result in reduced IOP and daily medication at follow-up through 12 months.

A new compact, portable device for rapid, high-definition meibomian gland imaging (LipiScan, TearScience) is an efficient screening tool for patients with complaints of dry eye and/or candidates for surgical procedures in which pre-existing dry eye could affect outcomes.

Charles L. Harris, MD, reviews safety and efficacy rates in a glaucoma case series after adding a proprietary laser system with probe to the surgical armamentarium.

CO2 laser-assisted sclerectomy performed with a proprietary laser system is a simplified filtration procedure that is showing good IOP-lowering efficacy and safety in eyes followed to 5 years.

Results from a second pivotal trial investigating latanoprostene bunod 0.024% (LBN) are consistent with another identically designed study showing that not only is LBN non-inferior to timolol maleate 0.5% for lowering IOP, but it has significantly greater efficacy.

One-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.

Learn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond.

The bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.

Sabin Dang, MD, didn’t have as clear cut of a journey to the ophthalmic world as many would expect. While today he spends his working hours improving visual outcomes of patients at Ophthalmic Consultants of Boston, a few years ago you would have found him creating coding software in his IT consulting company to help businesses grow.

A new trabecular meshwork excision blade takes a new approach in IOP reduction.

Ceeable, a web-based, mobile digital technology designed to detect early-stage eye diseases-an innovation that can help shape 21st century medicine-was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.

Uveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.

From the silent auction, art sales, and an opera performance, the 2016 Glaucoma 360 gala was one not to be soon forgotten.

Rishi Singh, MD, explains a case with a patient with moderately severe DME.

Santen Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.

Hear about the case, view the slides, and vote on your responses.

Change is an inside job. Are you unhappy with your practice’s growth? Take the often overlooked option of offensive time management. Actively shape your day by establishing what I like to call selective control.

It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.

A portable non-mydriatic fundus camera was found useful in grading cup-to-disc ratio as part of glaucoma screening compared with a standard tabletop mydriatic fundus camera.

A visit to two innovative optical shops reveals differing portraitures of providing better customer experience and increasing capture rate.

Cataract surgery with or without intravenous sedation can be a factor in the clinical experience. Moving to sublingual sedation may be the next step in safety and comfort for a demanding patient demographic.